盐酸安非他酮/托吡酯（Qsymia™）复方制剂治疗肥胖的临床实用性。
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.
机构信息
Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
出版信息
Diabetes Metab Syndr Obes. 2013 Apr 8;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013.
Abstract
Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications - seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.
摘要
Qsymia™（Vivus Inc，美国加利福尼亚州山景城），一种包含苯丁胺和缓释托吡酯的复方制剂，自 2012 年 9 月起在美国获准用于肥胖症的治疗。苯丁胺是一种厌食药，被批准用于短期肥胖治疗，而托吡酯则被批准用于非减肥适应症——癫痫发作和偏头痛预防。与单一药物治疗相比，联合治疗的减重效果更为显著。联合治疗中出现的不良反应与组成药物的已知副作用特征一致；致畸性、心率略有增加、精神和认知不良反应以及代谢性酸中毒是需要关注的问题。
相似文献
1
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.盐酸安非他酮/托吡酯（Qsymia™）复方制剂治疗肥胖的临床实用性。
Diabetes Metab Syndr Obes. 2013 Apr 8;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013.
2
Phentermine and topiramate extended release (Qsymia™): first global approval.盐酸苯丁胺和托吡酯缓释片（Qsymia™）：全球首次批准。
Drugs. 2012 Oct 22;72(15):2033-42. doi: 10.2165/11640860-000000000-00000.
3
A review of the metabolic effects of controlled-release Phentermine/Topiramate.关于控释苯丁胺/托吡酯对代谢影响的综述。
Hormones (Athens). 2013 Oct-Dec;12(4):507-16. doi: 10.14310/horm.2002.1438.
4
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.苯丁胺、托吡酯及其联合用药治疗脂肪代谢障碍（“病态肥胖”）和代谢性疾病。
Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16.
5
Phentermine/Topiramate: Pediatric First Approval.苯丁胺/托吡酯：儿科首次批准。
Paediatr Drugs. 2022 Nov;24(6):715-720. doi: 10.1007/s40272-022-00532-z.
6
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.低剂量、控释型、苯丁胺与托吡酯复方制剂对超重和肥胖成年人体重及相关合并症的影响（CONQUER）：一项随机、安慰剂对照、3 期临床试验。
Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8.
7
Phentermine and topiramate extended-release for the obesity: new kids on the block.用于治疗肥胖症的缓释苯丁胺和托吡酯：新出现的药物。
Recent Pat Cardiovasc Drug Discov. 2013 Apr;8(1):35-41. doi: 10.2174/15748901112079990012.
8
Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.肥胖与心脏代谢风险的管理——盐酸苯丁胺/缓释托吡酯的作用
Diabetes Metab Syndr Obes. 2014 Feb 12;7:35-44. doi: 10.2147/DMSO.S38979. eCollection 2014.
9
The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?新型减肥药：氯卡色林和托吡酯/安非拉酮：选择有限？
JAMA Intern Med. 2014 Apr;174(4):615-9. doi: 10.1001/jamainternmed.2013.14629.
10
Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.苯丁胺/托吡酯用于减肥及治疗肥胖相关的不良代谢后果。
Drugs Today (Barc). 2011 Dec;47(12):903-14. doi: 10.1358/dot.2011.47.12.1718738.
引用本文的文献
1
Addressing the challenge of obesity in primary care: a review of effective interventions and implementation strategies.应对基层医疗中肥胖问题的挑战：有效干预措施与实施策略综述
Diabetol Metab Syndr. 2025 Aug 22;17(1):351. doi: 10.1186/s13098-025-01925-z.
2
Evaluation of the efficacy and safety of controlled-release phentermine/topiramate in adults with obesity in Korea: A randomized, double-blind, placebo-controlled, phase 4 trial (QUEEN's study).在韩国肥胖成人中评估缓释苯丁胺/托吡酯的疗效和安全性：一项随机、双盲、安慰剂对照的4期试验（QUEEN研究）。
Diabetes Obes Metab. 2025 Mar;27(3):1242-1250. doi: 10.1111/dom.16119. Epub 2024 Dec 20.
3
Drug Repurposing: A Leading Strategy for New Threats and Targets.药物重新利用：应对新威胁和新靶点的首要策略。
ACS Pharmacol Transl Sci. 2024 Apr 1;7(4):915-932. doi: 10.1021/acsptsci.3c00361. eCollection 2024 Apr 12.
4
Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review.托吡酯（妥泰）：在体重减轻管理中的作用演变：一项叙述性综述
Life (Basel). 2023 Aug 31;13(9):1845. doi: 10.3390/life13091845.
5
Unraveling Obesity: Transgenerational Inheritance, Treatment Side Effects, Flavonoids, Mechanisms, Microbiota, Redox Balance, and Bioavailability-A Narrative Review.解析肥胖：跨代遗传、治疗副作用、黄酮类化合物、机制、微生物群、氧化还原平衡及生物利用度——一篇叙述性综述
Antioxidants (Basel). 2023 Aug 3;12(8):1549. doi: 10.3390/antiox12081549.
6
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.调节能量平衡以对抗肥胖的药理学策略的最新进展。
RSC Med Chem. 2023 Jun 14;14(8):1429-1445. doi: 10.1039/d3md00107e. eCollection 2023 Aug 16.
7
Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study.在肥胖人群中，与利拉鲁肽相比，中草药与更高的体重减轻相关：一项真实世界的比较队列研究。
Front Pharmacol. 2022 Sep 9;13:978814. doi: 10.3389/fphar.2022.978814. eCollection 2022.
8
Phytochemical Combination (-Synephrine, -Octopamine Hydrochloride, and Hispidulin) for Improving Obesity in Obese Mice Induced by High-Fat Diet.植物化学成分组合（辛弗林、盐酸辛可宁和毛蕊花糖苷）改善高脂肪饮食诱导肥胖小鼠的肥胖
Nutrients. 2022 May 23;14(10):2164. doi: 10.3390/nu14102164.
9
Combined Anti-Adipogenic Effects of Hispidulin and -Synephrine on 3T3-L1 Adipocytes.槐皮素和辛弗林联合抗 3T3-L1 脂肪细胞形成作用。
Biomolecules. 2021 Nov 25;11(12):1764. doi: 10.3390/biom11121764.
10
New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review.新型肠促胰岛素联合疗法在肥胖与代谢领域的研究进展：一项系统综述
Pharmaceuticals (Basel). 2021 Aug 28;14(9):869. doi: 10.3390/ph14090869.
本文引用的文献
1
Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.唑尼沙胺用于肥胖成年人减重：一项为期1年的随机对照试验。
Arch Intern Med. 2012 Nov 12;172(20):1557-64. doi: 10.1001/2013.jamainternmed.99.
2
A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.一项关于口服缓释剂型苯丁胺/托吡酯治疗肥胖成年人阻塞性睡眠呼吸暂停的随机、双盲、安慰剂对照研究。
Sleep. 2012 Nov 1;35(11):1529-39. doi: 10.5665/sleep.2204.
3
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.为期两年的肥胖和超重成年人用控释苯丁胺/托吡酯持续减肥和代谢获益（SEQUEL）：一项随机、安慰剂对照、3 期扩展研究。
Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7.
4
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).在严重肥胖成年人中使用控释苯丁胺/托吡酯：一项随机对照试验（EQUIP）。
Obesity (Silver Spring). 2012 Feb;20(2):330-42. doi: 10.1038/oby.2011.330. Epub 2011 Nov 3.
5
Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force.成年人肥胖相关初级保健治疗的效果：美国预防服务工作组的系统证据回顾。
Ann Intern Med. 2011 Oct 4;155(7):434-47. doi: 10.7326/0003-4819-155-7-201110040-00006.
6
Topiramate-induced weight loss: a review.托吡酯引起的体重减轻：综述。
Epilepsy Res. 2011 Aug;95(3):189-99. doi: 10.1016/j.eplepsyres.2011.05.014. Epub 2011 Jun 17.
7
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.低剂量、控释型、苯丁胺与托吡酯复方制剂对超重和肥胖成年人体重及相关合并症的影响（CONQUER）：一项随机、安慰剂对照、3 期临床试验。
Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8.
8
Withdrawal of sibutramine in Europe.西布曲明在欧洲的撤市
BMJ. 2010 Feb 9;340:c824. doi: 10.1136/bmj.c824.
9
Combination therapy for obesity and metabolic disease.肥胖与代谢性疾病的联合治疗
Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):353-8. doi: 10.1097/MED.0b013e3283304f90.
10
Pharmacotherapy for the obese patient.肥胖患者的药物治疗
Prim Care. 2009 Jun;36(2):407-15. doi: 10.1016/j.pop.2009.01.004.
Zotero 插件